The Korean journal of internal medicine

  • 제30권1호
  • /
  • Pages.104-109
  • /
  • 2015
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent

  • Koo, Bon San (Division of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Hong, Seokchan (Division of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, You Jae (Division of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Yong-Gil (Division of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Chang-Keun (Division of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Yoo, Bin (Division of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine)
  • 투고 : 2013.09.24
  • 심사 : 2014.04.10
  • 발행 : 2015.01.01
⟨ 이전 논문 다음 논문 ⟩

초록

Background/Aims: To evaluate the impact on mortality of anti-tumor necrosis factor (anti-TNF) treatment of rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Methods: We retrospectively reviewed the medical records of 100 RA-ILD patients who visited our tertiary care medical center between 2004 and 2011, identified those treated with an anti-TNF agent, divided patients into non-survivor and survivor groups and evaluated their clinical characteristics and causes of death. Results: A total of 24 RA-ILD patients received anti-TNF therapy, of whom six died (25%). Mean age at initiation of anti-TNF therapy was significantly higher in the nonsurvivor versus survivor group (76 years [range, 66 to 85] vs. 64 years [range, 50 to 81], respectively; p = 0.043). The mean duration of anti-TNF treatment in the non-survivor group was shorter (7 months [range, 2 to 14] vs. 23 months [range, 2 to 58], respectively; p = 0.030). The duration of anti-TNF therapy in all nonsurviving patients was < 12 months. Pulmonary function test results at ILD diagnosis, and cumulative doses of disease-modifying drugs and steroids, did not differ between groups. Five of the six deaths (83%) were related to lung disease, including two diffuse alveolar hemorrhages, two cases of acute exacerbation of ILD, and one of pneumonia. The sixth patient died of septic shock following septic arthritis of the knee. Conclusions: Lung complications can occur within months of initial anti-TNF treatment in older RA-ILD patients; therefore, anti-TNF therapy should be used with caution in these patients.

키워드

참고문헌

  1. Tanoue LT. Pulmonary manifestations of rheumatoid arthritis. Clin Chest Med 1998;19:667-685. https://doi.org/10.1016/S0272-5231(05)70109-X
  2. Suzuki A, Ohosone Y, Obana M, et al. Cause of death in 81 autopsied patients with rheumatoid arthritis. J Rheumatol 1994;21:33-36.
  3. Olson AL, Swigris JJ, Sprunger DB, et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med 2011;183:372-378. https://doi.org/10.1164/rccm.201004-0622OC
  4. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006;355:704-712. https://doi.org/10.1056/NEJMct055183
  5. Vassallo R, Matteson E, Thomas CF Jr. Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. Chest 2002;122:1093-1096. https://doi.org/10.1378/chest.122.3.1093
  6. Hagiwara K, Sato T, Takagi-Kobayashi S, Hasegawa S, Shigihara N, Akiyama O. Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis. J Rheumatol 2007;34:1151-1154.
  7. Antoniou KM, Mamoulaki M, Malagari K, et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. Clin Exp Rheumatol 2007;25:23-28.
  8. Watson K, Symmons D, Griffiths I, Silman A. The British Society for Rheumatology biologics register. Ann Rheum Dis 2005;64 Suppl 4:iv42-iv43.
  9. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324. https://doi.org/10.1002/art.1780310302
  10. Dixon WG, Hyrich KL, Watson KD, et al. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2010;69:1086-1091. https://doi.org/10.1136/ard.2009.120626
  11. Khaja M, Menon L, Niazi M, Fuentes GD. Diffuse alveolar hemorrhage and acute respiratory distress syndrome during treatment of rheumatoid arthritis with etanercept. J Bronchology Interv Pulmonol 2012;19:228-231. https://doi.org/10.1097/LBR.0b013e3182608e01
  12. Panagi S, Palka W, Korelitz BI, Taskin M, Lessnau KD. Diffuse alveolar hemorrhage after infliximab treatment of Crohn’s disease. Inflamm Bowel Dis 2004;10:274-277. https://doi.org/10.1097/00054725-200405000-00016
  13. Daoussis D, Liossis SN, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford) 2010;49:271-280. https://doi.org/10.1093/rheumatology/kep093
  14. Lafyatis R, O’Hara C, Feghali-Bostwick CA, Matteson E. B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 2007;56:3167-3168. https://doi.org/10.1002/art.22847

피인용 문헌

  1. Adalimumab/etanercept : Various toxicities: 6 case reports vol.1577, pp.1, 2015, https://doi.org/10.1007/s40278-015-10430-6
  2. Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis vol.9, pp.suppl1, 2015, https://doi.org/10.4137/ccrpm.s23288
  3. Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist’s point of view vol.32, pp.4, 2017, https://doi.org/10.3904/kjim.2016.212
  4. Biologics-induced interstitial lung diseases in rheumatic patients: facts and controversies vol.17, pp.3, 2015, https://doi.org/10.1080/14712598.2017.1287169
  5. Reinterpreting Evidence of Rheumatoid Arthritis-Associated Interstitial Lung Disease to Understand Etiology vol.15, pp.4, 2015, https://doi.org/10.2174/1573397115666190116102451
  6. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis vol.58, pp.2, 2019, https://doi.org/10.1093/rheumatology/key208
  7. Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD) vol.79, pp.14, 2015, https://doi.org/10.1007/s40265-019-01178-x
  8. Diagnosis and management of connective tissue disease‐associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zeala vol.26, pp.1, 2015, https://doi.org/10.1111/resp.13977
  9. Mortality in Korean Patients With Rheumatoid Arthritis vol.28, pp.3, 2015, https://doi.org/10.4078/jrd.2021.28.3.113
  10. Revisión sistemática sobre el impacto de los fármacos en la enfermedad pulmonar intersticial difusa asociada a Artritis Reumatoide vol.17, pp.9, 2015, https://doi.org/10.1016/j.reuma.2020.04.015
  11. The role of lung ultrasound B-lines and serum KL-6 in the screening and follow-up of rheumatoid arthritis patients for an identification of interstitial lung disease: review of the literature, proposa vol.23, pp.1, 2015, https://doi.org/10.1186/s13075-021-02586-9